Comparative Pharmacology
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus MYTESI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: IMODIUM A D EZ CHEWS versus MYTESI.
IMODIUM A-D EZ CHEWS vs MYTESI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Loperamide is a synthetic piperidine derivative that acts directly on intestinal muscle to slow peristalsis, thereby reducing stool frequency and increasing stool consistency. It binds to μ-opioid receptors in the myenteric plexus of the gastrointestinal tract, decreasing acetylcholine release and inhibiting peristalsis. It has minimal central nervous system activity due to poor bioavailability and efflux by P-glycoprotein.
MYTESI (crofelemer) is a proanthocyanidin oligomer that acts locally in the gastrointestinal tract to inhibit chloride ion secretion by blocking both the cystic fibrosis transmembrane conductance regulator (CFTR) and calcium-activated chloride channels (CaCC) at the luminal surface of enterocytes, thereby reducing fluid and electrolyte secretion.
4 mg orally initially, then 2 mg after each unformed stool; maximum 8 mg/day for OTC use (prescription: up to 16 mg/day).
1 capsule (5 mg) orally three times daily, taken 30 minutes before meals.
None Documented
None Documented
Terminal elimination half-life is approximately 9–14 hours (mean ~10.8 hours) in healthy adults. In patients with hepatic impairment, half-life may be prolonged.
1.6 hours (mean terminal elimination half-life); clinical context: short half-life supports oral administration three times daily to maintain therapeutic levels.
Primarily hepatic metabolism with biliary excretion of metabolites; ~1% renal excretion of unchanged drug. Fecal elimination accounts for ~90% of the dose, mainly as conjugated metabolites, with ~1% as unchanged loperamide.
Primarily fecal (82-86%) as unchanged drug; renal excretion accounts for <1% of the dose.
Category C
Category C
Antidiarrheal
Antidiarrheal